Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F901318 CYP3A4 Inhibition Study
NCT02680808Phase 1Completed
- Sponsor
- F2G
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olorofim in invasive aspergillosis (IA), sponsored by F2G. Primary endpoint: Area Under Concentration/Time Curve at 24 hours. Started Jan 2016; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT02680808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680808.